The impact of folate pathway variants on the outcome of methotrexate therapy in rheumatoid arthritis patients.
Azhar M NomairAbeer Ali AbdelatiFatma I DwedarRehab ElnemrYasmine N KamelHanan Mohamed NomeirPublished in: Clinical rheumatology (2024)
The 80AA genotype of RFC-1 G80A and the 2R/3R or 3R/3R genotypes of TYMS 2R/3R are more vulnerable to the good consequences of MTX therapy. Key Points • Current recommendations support the gold standard role of MTX as a first-line monotherapy for RA patients. However, up to 40% of RA patients do not respond or exhibit partial response to MTX. • Persistent disease activity due to treatment unresponsiveness will affect the long-term outcomes in RA patients. • We aimed, through molecular genetic study, to identify the connection between three variants in the folate pathway of MTX metabolism and the response to methotrexate monotherapy in a cohort of RA patients.
Keyphrases
- disease activity
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- rheumatoid arthritis patients
- systemic lupus erythematosus
- prognostic factors
- clinical trial
- ankylosing spondylitis
- low dose
- combination therapy
- dna methylation
- stem cells
- copy number
- high dose
- single molecule
- study protocol
- interstitial lung disease
- double blind